CIK 0001725160 · Non-accelerated filer<br>Smaller reporting company
Zentalis Pharmaceuticals, Inc.
Sign in to watch- Ticker
- ZNTL
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 823607803
- Phone
- (858) 263-4333
- Business address
- 10275 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO, CA, 92121
- Former names
- Zentalis Pharmaceuticals, LLC, Zeno Pharma, LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-01-08 | EASTLAND JULIA MARIE CEO & President | Grant or award · Stock Option (Right to Buy) | +775,000 | 775,000 | ||
| 2025-12-31 | WALTERS GROUP 10% owner | Purchase | +6,459,973 | $1.20 | $7.8M | 13,509,973 |
| 2025-12-15 | Matrix Capital Management Company, LP 10% owner | Sale | −7,500,000 | $1.33 | $10.0M | 6,459,973 |
| 2025-10-01 | Bucher James B Chief Legal Officer | Grant or award · Stock Option (Right to Buy) | +400,000 | 400,000 | ||
| 2025-06-17 | Walker Luke Nathaniel Director | Grant or award | +57,603 | 144,284 | ||
| 2025-06-17 | Skvarka Jan Director | Grant or award | +57,603 | 207,154 | ||
| 2025-06-17 | Johnson David Michael Director | Grant or award | +57,603 | 250,421 | ||
| 2025-06-17 | Kariuki Enoch Director | Grant or award | +57,603 | 137,365 | ||
| 2025-06-17 | Myers Scott Dunseth Director | Grant or award | +57,603 | 338,795 | ||
| 2025-04-30 | Myers Scott Dunseth Director | Purchase | +21,000 | $1.40 | $29K | 281,192 |
| 2025-02-06 | Bruns Ingmar Chief Medical Officer | Purchase | +20,000 | $2.28 | $46K | 36,629 |
| 2025-02-03 | Vultaggio Vincent PAO and Interim PFO | Grant or award | +158,586 | 192,441 | ||
| 2025-02-03 | Vultaggio Vincent PAO and Interim PFO | Sale | −2,615 | $1.71 | $4K | 189,826 |
| 2025-02-03 | Vultaggio Vincent PAO and Interim PFO | Grant or award · Stock Option (Right to Buy) | +35,633 | 35,633 | ||
| 2025-02-03 | Lackner Mark Chief Scientific Officer | Grant or award | +335,907 | 527,224 | ||
| 2025-02-03 | Lackner Mark Chief Scientific Officer | Sale | −14,368 | $1.71 | $25K | 512,856 |
| 2025-02-03 | Lackner Mark Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +124,714 | 124,714 | ||
| 2025-02-03 | Paul Andrea Chief Legal Officer | Grant or award | +934,041 | 1,084,014 | ||
| 2025-02-03 | Paul Andrea Chief Legal Officer | Sale | −13,230 | $1.71 | $23K | 1,070,784 |
| 2025-02-03 | Paul Andrea Chief Legal Officer | Grant or award · Stock Option (Right to Buy) | +124,714 | 124,714 |
Page 2 of 8 · 160 trades